AUTL - Autolus Therapeutics

-

$undefined

N/A

(N/A)

Autolus Therapeutics NasdaqGS:AUTL Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Location: The Mediaworks, White City, London, W12 7FP, United Kingdom | Website: https://www.autolus.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

36.54M

Cash

588M

Avg Qtr Burn

-51.57M

Short % of Float

8.29%

Insider Ownership

18.09%

Institutional Own.

85.87%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AUCATZYL® (obecabtagene autoleucel) (obe-cel) Details
Acute lymphoblastic leukemia, Cancer, Blood cancer

Approved

Quarterly sales

AUTO4 Details
Peripheral T cell cancer

Phase 1/2

Update

AUTO1/22 (CD19 & CD22) Details
Cancer, Leukemia, Pediatric Acute lymphoblastic leukemia

Phase 1

Data readout

AUTO6NG Details
Solid tumor/s, Neuroblastoma

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas

Phase 1

Data readout

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Systemic lupus erythematosus

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia

Phase 1

Update

AUTO5 Details
T-cell lymphoma

Phase 1

Initiation

obe-cel Details
Multiple Sclerosis (MS)

Phase 1

Initiation

AUTO3 (CD19, CD22) Details
Lymphoma, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued